The facility, at CSL’s headquarters in Melbourne, Victoria will develop and manufacture supplies for clinical trials, creating some 330 highly-skilled jobs when fully operational in five years time.
CEO Brian McNamee said the facility will enable CSL to “build on our existing capabilities and research collaborations, further develop the nation’s biotechnology skills.”
The project is being supported by a $30m (€23m) grant from the Australian Government, which is part of an investment package designed to boost health technology in the country.
